Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
4.71 M
Value Traded
752.35 K
Short % Float
-
Days to Cover
7.8
-6.18%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
266.93 M
EPS (TTM)
-0.02
P/E Ratio
-
Ent. Value
330.72 M
Total Shares
1.71 B
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
NWBO Catalyst Timeline
Dated clinical, regulatory and corporate events for Northwest Biotherapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Northwest Biotherapeutics, Inc.
9Total events
4Upcoming
1Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 2
TBD
T2Timing Guidance
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 3
●Restructuring LayoffsCorporate
NWBio expands US technical team and eliminates selected non-essential positions
●Oral PresentationDCVaxPresentation
Keynote presentation on personalized multi-target cancer immunotherapy at UK NHS CancerCare Oncology Conference
solid tumor cancerssource ↗
▲Partnership / LicenseDCVax®-LCorporate
Non-binding MOU with SPIMACO for DCVax-L in Saudi Arabia
glioblastoma brain cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How NWBO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every NWBO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MALIK NAVIDDirector | Sell | -657,895 23,339,393 held | $0.38 | 07/26/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in NWBO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NWBO for Q2 2026. | ||||
Ownership Trends
NWBO Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
69.4M
Shares Sold Short
-5.1% vs prior count
7.8 High
Days to Cover
trading days of normal volume to buy every short share back
8.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NWBO ranks across every disease it competes in
Competitive Position is a premium feature
See how NWBO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNWBO News
-NWBO
Oct 26, 2026▲ +11.7%on this news
Northwest Biotherapeutics Announces Expansion of Its Technical Team
Northwest Biotherapeutics has expanded its technical team to enhance operations, focusing on scaling production and preparing for clinical trials beyond brain cancer. The company has hired key personnel in Quality Assurance, Information Technologies, and Investor Relations. While increasing headcount, it is also eliminating some positions to balance costs.
Read more →-NWBO
Oct 6, 2026Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference
Northwest Biotherapeutics announced that Dr. Marnix Bosch will present at the UK NHS CancerCare Oncology Conference on October 6. The presentation will cover personalized cancer treatments, focusing on dendritic cell-based vaccines like DCVax®. The company aims to improve cancer care without the toxicities of traditional therapies.
Read more →-NWBO
Aug 6, 2026▲ +11.4%on this news
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
Northwest Biotherapeutics has signed a non-binding MOU with SPIMACO to collaborate on the approval and commercialization of its DCVax-L product for glioblastoma in Saudi Arabia. The partnership aims to facilitate technology transfer and localized manufacturing, aligning with Saudi Arabia's Vision 2030. SPIMACO will handle regulatory interactions and marketing efforts.
Read more →About Northwest Biotherapeutics, Inc.
BIOPHARMAWATCH ELITE
Trade the next NWBO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime